Moderna's combined COVID-19 and flu vaccine has shown promising results in a Phase 3 clinical trial, outperforming currently available standalone vaccines for both viruses. The study, published in the Journal of the American Medical Association, revealed that the combined mRNA shot generated a stronger immune response against both influenza and SARS-CoV-2, the virus that causes COVID-19.
The trial involved a large group of participants and compared the effectiveness of Moderna's combination vaccine against separate flu and COVID-19 shots. The results indicated that the combined vaccine was more effective in preventing infection and illness caused by both viruses. Researchers believe this combined approach could streamline vaccination efforts, making it easier for people to stay protected against respiratory illnesses.
Moderna is continuing to evaluate the long-term effectiveness and safety of the combined vaccine. The company plans to seek regulatory approval for the shot, potentially making it available to the public in the future. A combined vaccine could offer a more convenient and efficient way to protect against both COVID-19 and the flu, especially for vulnerable populations.
Moderna's Combination COVID-19 and Flu Shot Shows Promising Results
Moderna's experimental vaccine, which combines protection against COVID-19 and the flu, has demonstrated superior performance compared to existing individual vaccines in a large clinical trial. The Phase 3 trial results, published in the Journal of the American Medical Association, indicate a stronger immune response against both viruses. This combined shot could simplify vaccination efforts and potentially offer more convenient protection for individuals. Further studies are underway to assess long-term effectiveness and safety.
Source: Read the original article at NBC